Abstract
버섯 다당류 <TEX>${\beta}$</TEX>-glucan의 항암 활성을 확인하기 위하여 영지균사체로부터 단백다당류(GLP)를 분리하고 Sarcoma-180 육종암을 이식시킨 마우스에 복강 투여하여 항암활성을 확인하였다. 육종암이 서혜부에 이식된 마우스에 GLP를 20 mg/kg의 농도로 10일간 복강투여 한 후 30일차에 확인한 결과, Sarcoma-180 육종암은 대조군대비 71.4% 억제되었으며, 마우스의 혈청, 종양조직 및 간조직 내의 TNF-<TEX>${\alpha}$</TEX>의 농도는 대조군보다 높게 나타났다. 따라서 GLP는 생체 내 TNF-<TEX>${\alpha}$</TEX>의 양적증가를 유도하며, 종양괴사 또는 에폽토시스와 연관된 육종암의 생장억제가 확인되었다. 이때 생장이 억제된 육종암 세포의 미세구조를 관찰한 결과, 상대적으로 큰 핵과 세포의 에폽토시스에서 전형적으로 보여지는 염색질 응축이 관찰되었으며, 핵막은 특징적으로 뭉쳐져 불규칙한 모양을 나타내었다. 따라서 영지에서 분리된 GLP는 종양 세포의 에폽토시스를 유도하여 종양의 성장을 억제하는 것으로 여겨진다. Mushroom-derived <TEX>${\beta}$</TEX>-glucan, a polysaccharide (GLP) isolated from the mycelium of Ganoderma lucidum, was previously shown to have inhibitory effects against tumor-bearing mice in vivo. We investigated the apoptotic effect of mushroom-derived <TEX>${\beta}$</TEX>-glucan in a sarcoma-180 tumor cell- bearing mice model using an ELISA to determine the levels of tumor necrosis factor-<TEX>${\alpha}$</TEX> (TNF-<TEX>${\alpha}$</TEX>) in the mice. The morphology of the tumor cells was assessed with transmission electron microscopy (TEM). GLP was injected into the tumor-bearing mice at a dose (i.p.) of 20 mg/kg for 10 days. After 30 days, the tumor mass from the inguinal region was collected, weighed, and assayed using TEM and a TNF-<TEX>${\alpha}$</TEX> ELISA kit. The tumors that developed in the mice treated with GLP were 71.4% smaller than those in the control group, showing the ability of GLP to inhibit tumor growth. The levels of TNF-<TEX>${\alpha}$</TEX> in the serum of the sarcoma-180 bearing mice were 12 times greater than in the serum of the nonbearing tumor mice. An ultrastructural study demonstrated that the GLP-treated sarcoma-180 tumor cells were condensed, with rearranged chromatin. In addition, the marginated chromatin in nucleus induced the nuclear compartment, and there were many vacuolization in the cell. GLP could be an effective apoptosis-inducing compound in sarcoma-type cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.